Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olinciguat in achalasia
NCT02931565Phase 2Terminated
- Sponsor
- Cyclerion Therapeutics
- Start
- Apr 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in achalasia comparing IW-1701 with Placebo (2 arms). Primary endpoints: Treatment Emergent Adverse Events at Day 21, Supine Bolus Flow Time and 7 more. Started Apr 2017; status: terminated.
02
Drugs
olinciguat
03
Conditions
achalasia
Beyond the preview
Go deeper on NCT02931565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02931565.